A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Trotabresib (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
Most Recent Events
- 05 Jul 2024 Status changed from completed to discontinued. (Reason the study was stopped: Business objectives have changed.)
- 26 Jun 2024 Status changed from active, no longer recruiting to completed.
- 23 May 2024 Planned End Date changed from 9 May 2024 to 30 May 2024.